MARAGANORE JOHN 4

What Happened

• John Maraganore, a director of Beam Therapeutics Inc. (BEAM), was granted a derivative award on 2026-06-03 covering 19,676 shares. The filing shows an acquisition at $0.00 (derivative grant), indicating an option-type award rather than an open-market purchase or sale. This is a grant to a board member, not a purchase that required cash outlay.

Key Details

• Transaction date: 2026-06-03; SEC filing date: 2026-06-05 (timely filing).
• Amount granted: 19,676 shares (derivative award) at $0.00 listed in the filing.
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: The option vests in full on the earlier of the first anniversary of the grant date and immediately prior to the next annual meeting, subject to continued service on the board (see footnote F1).
• No indication in the filing of immediate exercise, sale, tax withholding, or a 10b5-1 plan.

Context

• This report documents a standard board compensation grant (an equity award/option) rather than a market purchase or sale. Such grants are routine for directors and compensate service; they do not by themselves indicate the director bought or sold stock on the open market.
• Because the award vests based on continued service over roughly one year, any future shares realized will depend on Maraganore remaining on the board through the vesting date.